Safety and Tolerability Study of Drug to Treat Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Registration Number
- NCT00044005
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Brief Summary
The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 98
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Lurasidone 80mg Lurasidone 80mg Lurasidone 80mg oral tablet Lurasidone 20 mg Lurasidone 20 mg Lurasidone 20 mg oral tablet Lurasidione 40 mg Lurasidone 40 mg Lurasidone 40 mg oral tablet
- Primary Outcome Measures
Name Time Method Number of Participants With Adverse Events 6-months The primary objective of this 6-month open-label study was to evaluate the safety of 3 doses of lurasidone.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (26)
Birmingham Psychiatry Pharmaceutical
🇺🇸Birmingham, Alabama, United States
Institute for Psychopharmacology Research
🇺🇸Cerritos, California, United States
CNS Network
🇺🇸Garden Grove, California, United States
California Clinical Trials Medical Group
🇺🇸Glendale, California, United States
Optimum Health Services
🇺🇸La Mesa, California, United States
University of California, Irvine
🇺🇸Orange, California, United States
California Neuropsychopharmacology Clinical Research Institute
🇺🇸San Diego, California, United States
Psychiatric Institute of Washington
🇺🇸Washington, District of Columbia, United States
Comprehensive Neuroscience. Inc.
🇺🇸Melbourne, Florida, United States
Segal Institute for Clinical Research
🇺🇸North Miami, Florida, United States
Scroll for more (16 remaining)Birmingham Psychiatry Pharmaceutical🇺🇸Birmingham, Alabama, United States